

Modified Form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/521,394
	Filing Date	August 5, 2005
	First Named Inventor	Stamler et al.
	Group Art Unit	1612
	Examiner Name	Marcos L. Sznajdman
	Attorney Docket Number	24862-514N01US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	6,455,676	09/24/02	Weickert et al.			

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C8	Casadevall et al., "Increased blood hemoglobin attenuates splanchnic vasodilation in portal-hypertensive rats by nitric oxide inactivation", <i>Gastroenterol.</i> , 110(4):1156-1165 (1996).
	C9	Chen et al., "Identification of the enzymatic mechanism of nitroglycerin bioactivation", <i>PNAS</i> , 99(12): 8306-8311 (2002).
	C10	Chen et al., "An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation", <i>PNAS</i> , 102(34): 12159-12164 (2005).

*By the waiver of 37 CFR 1.98(a)(2)(ii) a copy of the U.S. Patent is not submitted.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.